Secretary of State Marco Rubio, speaking during a visit to India, says the US has not changed its policy on arms transfers or its policy on intelligence sharing with Ukraine. "There’s nothing being deliberately denied to Ukraine,” Rubio tells reporters in Mumbai. (Source: Bloomberg)
Victoria Fernandez, chief market strategist at Crossmark Global Investments, explains the factors she sees pointing to a slowdown in the US economy and markets. She speaks on “Bloomberg Surveillance.” (Source: Bloomberg)
WhatsApp's help pages carried hidden instructions for its support chatbot that told it not to recommend a data protection authority or regulator to users who could no longer delete their accounts, even though WhatsApp's own privacy policy for Europe tells users they can complain to one.
The text sat in the pages' code, never shown on screen, until it was removed by October 18. Whether the
In a new Nature Physics study, researchers found that fin regrowth in zebrafish is driven by a brief burst of growth signal at the fin tip, sized to the amount lost, which sets up gradients of Erk activity that guide the regrowth.
As the 2026 midterm elections draw near, candidates are often focused on currying favor among particular demographic groups. A new study of Asian American ethnic subgroups in the U.S. indicates that political segregation is just one form of spatial isolation that may be shaping Asian Americans' voting behavior and living environments.
The first named storm of this autumn is set to lash the UK and northwest Europe with heavy rain and wind in the coming days, potentially bringing some relief to elevated power prices.
(RTTNews) - Health In Tech, Inc. (HIT), an AI-enabled InsurTech platform company, Tuesday announced the appointment of Sanjay Shrestha as Chief Executive Officer, effective October 20, 2026.
(RTTNews) - Health In Tech, Inc. (HIT), an AI-enabled InsurTech platform company, Tuesday announced the appointment of Sanjay Shrestha as Chief Executive Officer, effective October 20, 2026.
Key PointsBristol Myers Squibb has a moderately high forward dividend yield, but that's not the main appeal with this undervalued pharmaceutical stock.
Key PointsBristol Myers Squibb has a moderately high forward dividend yield, but that's not the main appeal with this undervalued pharmaceutical stock.